An open chat with ... Beata Vertessy by Tsagakis, I et al.
EDITORIAL
An open chat with. . .Beata Vertessy
Ioannis Tsagakis1, Beata Vertessy2 and Duncan Wright1
1 FEBS Open Bio Editorial Office, Cambridge, UK
2 Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
doi:10.1002/2211-5463.13077
As FEBS Open Bio approaches its 10th anniversary,
we have decided it is an ideal time to give the members
of our prestigious Editorial Board an opportunity to
discuss their research, publishing, and the activities of
FEBS in the virtual pages of the journal. This new
interview series is being helmed by Professor Beata
Vertessy, who has been on the FEBS Open Bio Edito-
rial Board since 2013 and has recently been promoted
to Senior Editor. As the organizer, she has agreed to
give the inaugural interview.
Beata G. Vertessy was born in Budapest, Hungary. She
obtained M.Sc. degrees in chemical engineering from the
BME Budapest University of Technology, Hungary, in
1984, and in molecular biology from the University of
Chicago in 1987, Ph.D./C.Sc. from the E€otv€os Lorand
University and the Hungarian Academy of Sciences in
1991, and D.Sc. from the Hungarian Academy of
Sciences in 2001. Her laboratory (http://biostruct.org)
focusing on Genome Metabolism and Repair at the
Institute of Enzymology, Budapest, Hungary, was
started in 2000 based on funding from the Howard
Hughes Medical Institute, U.S.A., Wellcome Trust,
U.K., and Alexander von Humboldt-Stiftung, Germany.
In 2010, she also started a structural biology laboratory
at the BME Budapest University of Technology and
Economics. The current research in her group aims to
understand prevention, recognition, and repair of uracil
in DNA from perspectives of structural and cell biology.
For those who are nonspecialists, how
would you describe your research?
Our research aims to understand the as of yet undiscov-
ered details of genomic chemistry. The textbook concept
that DNA consists of four bases is clearly not valid: sev-
eral rarer but highly important bases are also present in
DNA, and these play key roles in the regulation of nor-
mal and cancer cells. Our research is expected to reveal
novel pathways that will allow us to specifically target
cancer cells while causing minimal harm to normal cells.
Our research is also relevant in the context of infec-
tious diseases such as tuberculosis and malaria, since
DNA-based regulatory pathways in pathogenic
microbes are of great significance for biomedicine.
How did your fascination with the
metabolism of uracil-substituted DNA
start and where has that led your
research?
Throughout my undergraduate studies and my MSc in
chemical engineering, the chemical focus was of course
very prominent. Quantitative aspects and clear logical
thinking were also at the centre of my studies, and such
training was highly beneficial for my later research in
biochemistry and molecular biology. Uracil and thy-
mine nucleobases only differ by a single methyl group,
and it is fascinating to understand the different occur-
rences of these two bases in RNA versus DNA. It is also
quite extraordinary that this ‘simple’ methyl substitu-
tion between uracil and thymine requires an arsenal of
metabolic pathways due to the inherent chemical chal-
lenge of introducing a methyl group onto the pyrimidine
ring. Because of this chemical challenge, there is a multi-
faceted competition for activated methyl groups in cellu-
lar metabolic pathways from nucleotide biosynthesis to
amino acid biosynthesis and epigenetic pathways.
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When I started working in the uracil–DNA field, it
was already known that DNA could contain uracil
either via thymine replacing misincorporation or via
deamination of cytosine. However, it was highly dis-
puted whether or not uracil in DNA had any physiologi-
cal role. We first showed the significance of uracil-DNA
in the development of Drosophila (fruitfly) and then
aimed to characterize the quantitative patterns of uracil
genomic distribution in different models, a task which
required us to develop new tools. Our recent identifica-
tion of uracil–DNA patterns revealed an intriguing new
mechanism for drug action in human cancer cells [1]
What are some limitations in your
field of research? How are people
trying to overcome these?
A true and valid understanding of DNA chemistry is
paradoxically and unfortunately greatly impeded by
next-generation genome-wide sequencing technologies.
This may sound counterintuitive, but the reason for this
is that the vast majority of DNA sequencing methods
rely on reading the sequence of bases as they are incor-
porated into the newly synthesized DNA strand follow-
ing Watson-Crick base pairing rules. In these methods,
only the four canonical DNA building blocks (dATP,
dGTP, dTTP, and dCTP) are used, so the readout will
also be limited to these four nucleotides with adenine,
guanine, thymine, and cytosine bases.
However, let’s consider a situation where the template
strand contains both cytosine and also a noncanonical
analogue, for example, methyl-cytosine. Both cytosine
and its methyl-derivative will pair with guanine, so the
sequencing readout will hide this difference. Similarly,
both thymine and uracil base pair with adenine—again,
sequencing is unable to make this distinction, and there-
fore, the readout fails to reveal key information on tem-
plate strand composition and sequence. Clever chemical
solutions and biotechnology advances are required to
decipher the true DNA sequence, and numerous research
groups, including ours, work on these problems.
You moved around quite a bit during
your training and early career—what
stimulated your choices of institution
during that time and how did these
choices help shape your future
research focus?
For a successful scientific academic career, it is indispens-
able to learn and acquire experience in various research
laboratories and on multiple projects to develop the key
competencies required. For me, it was of great impor-
tance to undertake highly diverse projects frommetabolic
regulation and erythrocyte membrane elasticity to
nucleotide metabolism and DNA damage and repair. A
life-changing grant from the Howard Hughes Medical
Institutes then allowed me to start the uracil in DNA pro-
ject in my own laboratory. To tackle research questions
on uracil–DNA, my laboratory uses diverse methodolo-
gies from structural biophysics to molecular and cell biol-
ogy—all of which are techniques I previously gained
experience in duringmy earlier postdoctoral positions.
You also chair the FEBS Advanced
Courses Committee and are an ex
officio member of the FEBS Network
and FEBS Education Committees. How
do your roles on these committees
help you support early career
researchers?
FEBS aims to facilitate the careers of young scientists
through multiple avenues. For the Advanced Courses,
where the fields cover hot topics in molecular life
sciences, our major goal is to allow the young scientist
to make personal contacts with the leaders of any
given field. We also look for feedback from the partici-
pants so that we can further improve these events.
The Network is a great platform on which to learn
and socialize—especially in the current pandemic situa-
tion. The Education events also focus on career plan-
ning and aim to address many key areas required to
build a successful career.
What’s your proudest achievement
outside of science?
Family—together with my husband, we have two chil-
dren and five grandchildren, and it is so much joy to
see how they grow and develop. It is also a great happi-
ness for me to work together with many young people
in my laboratory and combine education and research.
We are really a family-friendly environment in my
group—to date more than 20 babies have been born to
my students while they were working in my laboratory.
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